Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetic Models: Comparison and Selection Criterion

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

Pharmacokinetic Models: Overview

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...

Analysis of Population Pharmacokinetic Data

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Increased expression of autophagy-related proteins in keratocystic odontogenic tumours: its possible association with growth potential.

The British journal of oral & maxillofacial surgery·2014

Same author

Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.

Molecular cancer therapeutics·2014

Same author

The sabotage of the bacterial transcription machinery by a small bacteriophage protein.

Bacteriophage·2014

Same author

In vivo and in vitro evidence of the sex-dependent pharmacokinetics and disposition of G004, a potential hypoglycemic agent, in rats.

European journal of drug metabolism and pharmacokinetics·2014

Same author

Inositol pyrophosphates mediate the effects of aging on bone marrow mesenchymal stem cells by inhibiting Akt signaling.

Stem cell research & therapy·2014

Same author

Sequential release of autophagy inhibitor and chemotherapeutic drug with polymeric delivery system for oral squamous cell carcinoma therapy.

Molecular pharmaceutics·2014

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India

Published on: December 23, 2022

Reconstructing exposures from small samples using physiologically based pharmacokinetic models and multiple

Paul L Mosquin¹, Amy Collins Licata, Bing Liu

¹RTI International, Research Triangle Park, North Carolina, USA.

Journal of Exposure Science & Environmental Epidemiology

|May 8, 2008

Summary

Physiologically based pharmacokinetic (PBPK) models help estimate exposure with limited biomarker data. Adding more biomarkers or sampling times improves exposure estimates, balancing precision with practical factors.

More Related Videos

Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis

Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis

Published on: July 11, 2014

Related Experiment Videos

Last Updated: Jul 5, 2026

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India

Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India

Published on: December 23, 2022

Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis

Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis

Published on: July 11, 2014

Area of Science:

Environmental Health
Toxicology
Pharmacokinetics

Background:

Population exposure surveys often have limited biomarker observations per individual.
Accurate exposure assessment is crucial for understanding health risks.

Purpose of the Study:

To investigate the optimal strategy for using physiologically based pharmacokinetic (PBPK) models to infer exposure with limited biomarker data.
To evaluate the trade-off between sampling multiple biomarkers versus multiple time points.

Main Methods:

Simulation-based approach using a revised chlorpyrifos PBPK model.
Investigated oral and dermal exposure routes.
Varied levels of analytic measurement error were included.

Main Results:

Adding more biomarkers at a single time point significantly increases information.
Increasing sampling times provides more information than adding biomarkers.
Estimate precision of exposed dose correlates with biomarker measurement analytic precision.

Conclusions:

Balancing the number of biomarkers and sampling times is key for efficient exposure estimation.
Consideration of cost and intrusiveness is necessary for practical application.
PBPK models offer a robust framework for exposure assessment in population studies.